Cibisatamab clinical trials
Also written RO6958688.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses cibisatamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2014 (1)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Cobimetinib (1) · Docetaxel (1) · Ciforadenant (1) · Pemetrexed (1) · Carboplatin (1) · Gemcitabine (1) · Linagliptin (1) · Ipatasertib (1)
Studies
Open first, then newest update. How each study uses cibisatamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)TerminatedPhase 1/2Hoffmann-La RocheNCT03337698Written as RO6958688
- A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal AdenocarcinomaTerminatedPhase 1Hoffmann-La RocheNCT03866239Written as Cibisatamab
- A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid TumorsCompletedPhase 1Hoffmann-La RocheNCT02324257Written as RO6958688
- A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid TumorsCompletedPhase 1Hoffmann-La RocheNCT02650713Written as RO6958688
Given beside what is tested · 1 — cibisatamab is usual care or a partner of the new treatment
Codes
What other systems call cibisatamab · ClinicalTrials.gg INT001404
- UNII (FDA) ZAM5J1ATF2CIBISATAMABOne source FDA
- NCI Thesaurus C120097CibisatamabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ZAM5J1ATF2 | CIBISATAMAB | One source FDA |
| NCI Thesaurus | C120097 | Cibisatamab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.